Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRK1 | P41145 | 1/20 | 0.62 |
| ▸ | PLAU | P00749 | 1/20 | 0.57 |
| ▸ | MAPT | P10636 | 2/20 | 0.53 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.53 |
| ▸ | THPO | P40225 | 1/20 | 0.53 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.53 |
| ▸ | USP2 | O75604 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | DRD2 | P14416 | 2/20 | 0.53 |
| ▸ | DRD3 | P35462 | 2/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL354978 | 1.00 | OPRK1 (0.62) | OPRK1PLAUMAPTNFKB1THPO | |
| SCHEMBL3020673 | 1.00 | OPRK1 (0.62) | OPRK1PLAUMAPTNFKB1THPO | |
| Hydrochloric Acid SCHEMBL4108116 | 0.98 | OPRK1 (0.61) | OPRK1PLAUMAPTNFKB1THPO | |
| Hydrochloric Acid SCHEMBL4117494 | 0.98 | OPRK1 (0.61) | OPRK1PLAUMAPTNFKB1THPO | |
| Hydrochloric Acid SCHEMBL4108112 | 0.98 | OPRK1 (0.61) | OPRK1PLAUMAPTNFKB1THPO | |
| SCHEMBL7451568 | 0.92 | DRD2 (0.62) | OPRK1PLAUMAPTNFKB1THPO | |
| SCHEMBL415207 | 0.92 | DRD2 (0.62) | OPRK1PLAUMAPTNFKB1THPO | |
| Hydrochloric Acid SCHEMBL21810869 | 0.91 | DRD2 (0.61) | OPRK1PLAUMAPTNFKB1THPO | |
| Trifluoroacetic Acid SCHEMBL4777095 | 0.85 | OPRK1 (0.51) | OPRK1MAPTNFKB1THPOHIF1A | |
| SCHEMBL615229 | 0.84 | CA1 (0.50) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 111 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025217336-A1 | CYSTEINE COVALENT MODIFIERS OF AKT1 AND USES THEREOF | TERREMOTO BIOSCIENCES, INC. (US) | 2025-10-16 | — | — | WO | disclosed |
| US-12162888-B2 | Carboxamides as ubiquitin-specific protease inhibitors | VALO HEALTH, INC. (US) | 2024-12-10 | — | — | US | disclosed |
| CN-112867712-B | Carboxamide as ubiquitin-specific protease inhibitor | 瓦洛早期发现股份有限公司 | 2024-07-16 | — | — | CN | disclosed |
| CN-109810111-B | Pyrazolopyrimidine compound, and preparation method and application thereof | 上海医药集团股份有限公司 | 2023-10-27 | — | — | CN | disclosed |
| US-11524966-B1 | Carboxamides as ubiquitin-specific protease inhibitors | VALO HEALTH, INC. (US) | 2022-12-13 | — | — | US | disclosed |
| US-20210323975-A1 | CARBOXAMIDES AS UBIQUITIN-SPECIFIC PROTEASE INHIBITORS | VALO EARLY DISCOVERY, INC. | 2021-10-21 | — | — | US | disclosed |
| US-20210323975-A1 | CARBOXAMIDES AS UBIQUITIN-SPECIFIC PROTEASE INHIBITORS | VALO EARLY DISCOVERY, INC. | 2021-10-21 | — | — | US | disclosed |
| EP-3833661-A1 | CARBOXAMIDES AS UBIQUITIN-SPECIFIC PROTEASE INHIBITORS | Valo Early Discovery, Inc. (US) | 2021-06-16 | — | — | EP | disclosed |
| CN-112867712-A | Carboxamides as ubiquitin-specific protease inhibitors | 瓦洛早期发现股份有限公司 | 2021-05-28 | — | — | CN | disclosed |
| EP-3665169-A1 | CARBOXAMIDES AS UBIQUITIN-SPECIFIC PROTEASE INHIBITORS | Forma Therapeutics, Inc. (US) | 2020-06-17 | — | — | EP | disclosed |
| US-20050075324-A1 | Melanin concentrating hormone antagonists | THE PROCTER & GAMBLE COMPANY (US) | 2005-04-07 | — | — | US | disclosed |
| US-20050075363-A1 | Isothiazoloquinolones and related compounds as anti-infective agents | ACHILLION PHARMACEUTICALS, INC. | 2005-04-07 | — | — | US | disclosed |
| WO-2005019228-A1 | ISOTHIAZOLOQUINOLONES AND RELATED COMPOUNDS AS ANTI-INFECTIVE AGENTS | ACHILLION PHARMACEUTICALS, INC. (US) | 2005-03-03 | — | — | WO | disclosed |
| US-20050014749-A1 | analgesics; antiinflammatory agents; antiarthritic agents;Alzheimer's disease; cirrhosis; antiallergens; antihistamines ; anticancer agents; vision defects | AMGEN INC. | 2005-01-20 | — | — | US | disclosed |
| EP-1457570-A1 | PROCESS FOR PREPARATION OF 2-AMINOTETRALIN DERIVATIVES AND INTERMEDIATES THEREOF | KANEKA CORPORATION (JP) | 2004-09-15 | — | — | EP | disclosed |
| US-5681961-A | TREATMENT AND/OR PREVENTION OF THROMBOEMBOLIC DISORDERS, ARTERIOSCLEROSIS, METASTASIS. ISCHEMIA, ASTHMA, ALLERGIES | DR. KARL THOMAE GMBH (DE) | 1997-10-28 | — | — | US | disclosed |
| EP-0397044-B1 | Arylsulfonamides, medicines containing these compounds and process for their preparation | THOMAE GMBH DR K (DE) | 1995-12-27 | — | — | EP | disclosed |
| US-5426119-A | Thromboxane antagonists | DR. KARL THOMAE GMBH (DE) | 1995-06-20 | — | — | US | disclosed |
| US-5294626-A | Thromboxane synthesis inhibitors and anticoagulants | DR. KARL THOMAS GMBH (DE) | 1994-03-15 | — | — | US | disclosed |
| EP-0397044-A2 | Arylsulfonamides, medicines containing these compounds and process for their preparation | Dr. Karl Thomae GmbH (DE) | 1990-11-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050075324-A1 | Melanin concentrating hormone antagonists | MCHR1, MCHR2, MC1R | OPRK1 90/4885PLAU 3622/4885MAPT 3017/4885 |
| US-11524966-B1 | Carboxamides as ubiquitin-specific protease inhibitors | USP28, USP25, USP24 | OPRK1 3379/4885PLAU 1018/4885MAPT 2661/4885 |
| US-20050075363-A1 | Isothiazoloquinolones and related compounds as anti-infective agents | TOP1, IRF3, RECQL | OPRK1 3473/4885PLAU 4729/4885MAPT 4593/4885 |
| US-20210323975-A1 | CARBOXAMIDES AS UBIQUITIN-SPECIFIC PROTEASE INHIBITORS | USP28, USP25, USP24 | OPRK1 3379/4885PLAU 1018/4885MAPT 2661/4885 |
| US-12162888-B2 | Carboxamides as ubiquitin-specific protease inhibitors | USP28, USP25, USP24 | OPRK1 3379/4885PLAU 1018/4885MAPT 2661/4885 |
| US-20050014749-A1 | analgesics; antiinflammatory agents; antiarthritic agents;Alzheimer's disease; cirrhosis; antiallergens; antihistamines ; anticancer agents; vision defects | ACHE, TNF, BCHE | OPRK1 17/4885PLAU 3365/4885MAPT 41/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.